Skip to main content

4 Result(s)

within Caterina Tatarelli Remove this filter

and

  1. Article

    Open Access

    Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

    Francesca Palandri, Elena M. Elli, Giuseppe Auteri… in Blood Cancer Journal (2023)

    Download PDF (1107 KB) View Article

  2. No Access

    Article

    Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

    Ruxolitinib is approved for polycythemia vera (PV) patients after failure to previous cytoreductive therapy, based on durable results observed in phase 3 trials. We report a multicenter retrospective study dem...

    Sara Pepe, Elena Rossi, Malgorzata Trawinska, Caterina Tatarelli… in Annals of Hematology (2022)

  3. No Access

    Article

    Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study

    The Gruppo Romano Mielodisplasie (GROM) conducted a retrospective study in 543 patients with myelodysplastic syndromes (MDS) to evaluate the safety and efficacy of erythropoiesis-stimulating agents (ESAs) in “...

    Francesco Buccisano, Anna Lina Piccioni, Carolina Nobile… in Annals of Hematology (2016)

  4. No Access

    Article

    Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study

    Myelodysplastic syndromes (MDS) are common in elderly patients. Recombinant human erythro-poietin (rHuEPO) has been widely used to treat anemia in lower risk MDS patients, but few data are known about rHuEPO t...

    Caterina Tatarelli, Anna Lina Piccioni, Luca Maurillo… in Annals of Hematology (2014)